Qiagen (NYSE:QGEN) Earns "Neutral" Rating from JPMorgan Chase & Co.

Key Points

• JPMorgan reaffirmed its “neutral” rating on Qiagen but lowered its price target from $55 to $52, implying approximately 3.3% upside from the stock’s current price.
• Analyst sentiment remains cautious: Qiagen has a consensus “Hold” rating, with four Buy ratings and ten Holds, while the average price target is $44.43.
• Qiagen’s latest quarterly results modestly exceeded expectations, with EPS of $0.62 versus the $0.60 consensus and revenue of $535.04 million versus $527.50 million expected. Investors are also focused on EQT’s proposed $12.1 billion all-cash acquisition, which introduces deal-completion risks.

Qiagen (NYSE:QGEN - Get Free Report)'s stock had its "neutral" rating reaffirmed by analysts at JPMorgan Chase & Co. in a research note issued to investors on Thursday, Benzinga reports. They presently have a $52.00 target price on the stock, down from their prior target price of $55.00. JPMorgan Chase & Co.'s price target would suggest a potential upside of 3.30% from the stock's current price.

A number of other analysts have also issued reports on QGEN. Stifel Nicolaus set a $40.00 price target on shares of Qiagen in a research note on Friday, August 7th. Citigroup reissued a "neutral" rating and issued a $45.00 price objective (up from $38.00) on shares of Qiagen in a research note on Monday, August 10th. Barclays set a $40.00 price objective on shares of Qiagen and gave the company an "equal weight" rating in a report on Friday, August 7th. Robert W. Baird upped their target price on shares of Qiagen from $50.00 to $52.00 and gave the stock an "outperform" rating in a research note on Thursday. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $48.00 price target on shares of Qiagen in a research report on Thursday, August 6th. Four equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, Qiagen presently has a consensus rating of "Hold" and an average target price of $44.43.

Qiagen Stock Up 0.7%

QGEN stock opened at $50.34 on Thursday. Qiagen has a 12 month low of $32.53 and a 12 month high of $57.81. The company has a market cap of $10.37 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 4.87 and a beta of 0.61. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. The firm has a 50-day moving average of $44.15 and a two-hundred day moving average of $40.51.

Qiagen (NYSE:QGEN - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.02. The company had revenue of $535.04 million during the quarter, compared to analysts' expectations of $527.50 million. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The firm's quarterly revenue was up .2% on a year-over-year basis. During the same period in the prior year, the business earned $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, analysts forecast that Qiagen will post 2.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in QGEN. Assenagon Asset Management S.A. lifted its stake in Qiagen by 1.9% during the third quarter. Assenagon Asset Management S.A. now owns 15,722 shares of the company's stock worth $691,000 after purchasing an additional 286 shares during the last quarter. Allworth Financial LP increased its stake in Qiagen by 20.8% in the second quarter. Allworth Financial LP now owns 1,841 shares of the company's stock valued at $72,000 after purchasing an additional 317 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Qiagen by 46.8% during the first quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company's stock worth $110,000 after purchasing an additional 876 shares in the last quarter. Quadrant Capital Group LLC lifted its position in shares of Qiagen by 2.4% during the 3rd quarter. Quadrant Capital Group LLC now owns 42,660 shares of the company's stock worth $1,938,000 after buying an additional 1,003 shares during the last quarter. Finally, Hilltop National Bank purchased a new stake in shares of Qiagen during the 2nd quarter worth approximately $50,000. Hedge funds and other institutional investors own 70.00% of the company's stock.

Key Headlines Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: EQT takeover offer is the main catalyst. EQT has agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per share for all outstanding shares. The proposal confirms earlier reports that EQT was in advanced discussions and gives investors a potential cash-exit value. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
• Positive Sentiment: Preliminary Q3 results were solid. Qiagen reported preliminary net sales of $548 million and adjusted diluted EPS of $0.65, both at reported and constant exchange rates. The results indicate continued operating resilience ahead of the company’s full Q3 report scheduled for November 4, 2026. QIAGEN reports preliminary Q3 2026 results
• Positive Sentiment: Robert W. Baird raised its target. Baird increased its Qiagen price target from $50 to $52 and maintained an “outperform” rating, signaling further potential upside if the transaction does not fully determine the share price. Baird raises Qiagen price target
• Neutral Sentiment: The takeover now shifts attention from fundamentals to deal completion. Investors will likely focus on shareholder, regulatory and other closing conditions, as well as whether the proposed consideration represents the final value available to shareholders.
• Negative Sentiment: Transaction risk remains. Until the EQT acquisition closes, Qiagen remains exposed to potential delays, revised terms or failure to complete the deal. The takeover also limits the near-term importance of older standalone valuation estimates, including the previously reported brokerage consensus target of $43.93.

About Qiagen

QIAGEN N.V. NYSE: QGEN is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.